APPLICATION
ANDA216274
TYPE
ANDA
ORIGINAL APPROVAL
2023-10-02
LATEST ACTION
2025-01-30
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription
Products
POTASSIUM PHOSPHATESPrescription
POTASSIUM PHOSPHATE, DIBASIC 3.54GM/15ML (236MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 3.36GM/15ML (224MG/ML) · SOLUTION · INTRAVENOUS
POTASSIUM PHOSPHATESPrescription
POTASSIUM PHOSPHATE, DIBASIC 11.8GM/50ML (236MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 11.2GM/50ML (224MG/ML) · SOLUTION · INTRAVENOUS
POTASSIUM PHOSPHATESPrescription
POTASSIUM PHOSPHATE, DIBASIC 1.18GM/5ML (236MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 1.12GM/5ML (224MG/ML) · SOLUTION · INTRAVENOUS
Approval history
2025-01-30Manufacturing (CMC) · Supplement 2 · standardAP
2023-10-02UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.